Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-30a-5p mimetics
- Development stage
- Preclinical
- Lead developer
- Kaohsiung Chang Gung Memorial Hospital
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
microRNA-30a-5p mimetics are synthetic RNA molecules designed to restore the function of the endogenous tumor suppressor miR-30a-5p, which is frequently downregulated in various cancers, including upper tract urothelial carcinoma (UTUC). These mimetics act by binding to the 3' untranslated regions (UTRs) of target mRNAs, leading to translational repression or mRNA degradation. In UTUC, miR-30a-5p mimetics have been shown to inhibit cell proliferation, migration, and the epithelial-to-mesenchymal transition (EMT) by upregulating the tight junction protein claudin-5 and epithelial marker E-cadherin, while simultaneously suppressing mesenchymal markers such as vimentin, fibronectin, and alpha-smooth muscle actin.
- Other names
- miR-30a-5pmiR30a-5pmiR 30a-5pmicroRNA-30a-5pmicroRNA30a-5pmicroRNA 30a-5p
02
Targets
SNAI1 (Snail family transcriptional repressor 1)Vimentin messenger RNAMTDH (Metadherin)SNAI2 (Snail family transcriptional repressor 2)
Beyond the preview
Go deeper on microRNA-30a-5p mimetics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA-30a-5p mimetics.